NASDAQ: GRCE
Grace Therapeutics, Inc.
Healthcare · Biotechnology
Market Cap
$35.82M
52w High
$5.18
52w Low
$1.79
P/E
-4.80
Volume
46.75K
Outstanding Shares
15.47M
Price vs Fundamentals
Why The Stock Is Moving
Note: The most recent financial data is over 3 months old. Metrics shown may not reflect the latest reporting period.
What changed
The stock fell 26.74% over the last year. Free cash flow grew 27.97% over the trailing twelve months.
What the market seems to be pricing
Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.
What would invalidate this read
This read is wrong if revenue rolls over, margins compress again, or free cash flow keeps deteriorating. In that case the selloff would be catching up with weaker business quality rather than just a lower multiple.
Company profile
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
Valuation
Stock splits
Every 6 shares became 1
Every 8 shares became 1
Every 10 shares became 1
Profitability & growth
Analyst consensus
2
Buy
0
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Jun 22, 2026
Q2 FY26 · EPS est -$0.24 · Revenue est $900K
View